Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $4.07 million. The enterprise value is $3.56 million.
Important Dates
The last earnings date was Wednesday, May 20, 2026, before market open.
| Earnings Date | May 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Evogene has 10.41 million shares outstanding. The number of shares has increased by 40.53% in one year.
| Current Share Class | 10.41M |
| Shares Outstanding | 10.41M |
| Shares Change (YoY) | +40.53% |
| Shares Change (QoQ) | +11.70% |
| Owned by Insiders (%) | 0.81% |
| Owned by Institutions (%) | 5.59% |
| Float | 10.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.21 |
| Forward PS | 3.54 |
| PB Ratio | 0.51 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.79, with a Debt / Equity ratio of 0.25.
| Current Ratio | 2.79 |
| Quick Ratio | 2.75 |
| Debt / Equity | 0.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.78 |
Financial Efficiency
Return on equity (ROE) is -171.75% and return on invested capital (ROIC) is -68.73%.
| Return on Equity (ROE) | -171.75% |
| Return on Assets (ROA) | -32.89% |
| Return on Invested Capital (ROIC) | -68.73% |
| Return on Capital Employed (ROCE) | -109.27% |
| Weighted Average Cost of Capital (WACC) | 52.66% |
| Revenue Per Employee | $35,462 |
| Profits Per Employee | -$226,308 |
| Employee Count | 52 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 2.33 |
Taxes
In the past 12 months, Evogene has paid $5,000 in taxes.
| Income Tax | 5,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.40% in the last 52 weeks. The beta is 0.74, so Evogene's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | -71.40% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.96 |
| Relative Strength Index (RSI) | 13.59 |
| Average Volume (20 Days) | 3,221,119 |
Short Selling Information
The latest short interest is 313,620, so 2.61% of the outstanding shares have been sold short.
| Short Interest | 313,620 |
| Short Previous Month | 123,199 |
| Short % of Shares Out | 2.61% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.23 |
Income Statement
In the last 12 months, Evogene had revenue of $1.84 million and -$11.77 million in losses. Loss per share was -$1.37.
| Revenue | 1.84M |
| Gross Profit | -863,000 |
| Operating Income | -13.75M |
| Pretax Income | -17.50M |
| Net Income | -11.77M |
| EBITDA | -13.33M |
| EBIT | -13.75M |
| Loss Per Share | -$1.37 |
Full Income StatementBalance Sheet
The company has $13.05 million in cash and $2.03 million in debt, giving a net cash position of $11.02 million or $1.06 per share.
| Cash & Cash Equivalents | 13.05M |
| Total Debt | 2.03M |
| Net Cash | 11.02M |
| Net Cash Per Share | $1.06 |
| Equity (Book Value) | 7.99M |
| Book Value Per Share | -0.24 |
| Working Capital | 9.60M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$11.27 million and capital expenditures -$16,000, giving a free cash flow of -$11.29 million.
| Operating Cash Flow | -11.27M |
| Capital Expenditures | -16,000 |
| Depreciation & Amortization | 416,000 |
| Net Borrowing | -501,000 |
| Free Cash Flow | -11.29M |
| FCF Per Share | -$1.08 |
Full Cash Flow StatementMargins
| Gross Margin | -46.80% |
| Operating Margin | -745.66% |
| Pretax Margin | -949.08% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |